Healing minds.
Transforming lives.

BlackThorn Therapeutics is dedicated to improving the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments.
Who we are

About

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company that uses a novel and robust platform (INFORM™) to link behavioral deficits with brain physiology to discover and develop targeted treatments for neurobehavioral disorders. We envision a future where patients with neurobehavioral disorders are quickly recognized, accurately diagnosed and effectively treated.

Our Approach

Science

BlackThorn’s INFORM™ (Integrated Functional Objective Research Measures) platform creates an understanding of the core underlying pathophysiology of neurobehavioral disorders and generates objective neuromarkers.

INFORM enables BlackThorn to identify promising drug targets, select patients based on a physiologic link to those targets and objectively measure behavioral endpoints. The result is smaller trials, targeted to the right patients and with a higher probability of success.

Research & Development

Pipeline

BlackThorn is building a sustainable pipeline of treatments in major areas of unmet need. Our portfolio of first- and best-in-class small molecules modulates targets that are expressed in key brain regions of interest and that regulate behaviors integral to multiple disorders.

Program Discovery Preclinical Phase 1 Phase 2 Phase 3 NDA
BTRX-246040
BTRX Program 2
BTRX Program 3
BTRX Program 4
Program Phase
BTRX-246040 2
BTRX Program 2 Preclinical
BTRX Program 3 Preclinical
BTRX Program 4 Discovery
Our People

Team

BlackThorn is led by a team of seasoned professionals with deep expertise in neurobehavioral disorders and drug discovery and development.

Chief Executive Officer

Charles Gregory Vontz

Chief Scientific Officer

Bill Martin, Ph.D.

Chief Medical Officer

Annette Madrid, M.D.

Vice President, Operations and Corporate Development

Scott Forrest, Ph.D.

Chairman

Mark Corrigan, M.D.

View ›

Director

Kristina Burow

View ›

Director

John MacPhee

View ›

Director

Asish K. Xavier, Ph.D.

View ›

SAB Co-Chair

Steven E. Hyman, M.D.

View ›

SAB Co-Chair

Matthew W. State M.D., Ph.D.

View ›

Senior Advisor

Thomas O. Daniel, M.D.

View ›

Chemistry Advisor

Jin-Quan Yu, Ph.D.

View ›

SAB Member

John H. Krystal, M.D.

View ›

SAB Member

Paul Glimcher, Ph.D.

View ›

SAB Member

Alan Anticevic, Ph.D.

View ›

Scientific Founder

Hugh Rosen, M.D., Ph.D.

View ›

Scientific Founder

Edward Roberts, Ph.D.

View ›

Founder

Alex Tkachenko, Ph.D.

View ›

If you are interested in joining the BlackThorn team, please visit our careers page to learn about current job opportunities.

Our Newsroom

Recent News & Announcements

Apr 6, 2017
BlackThorn Therapeutics Announces Results of Preclinical Study of BTRX-335140, Demonstrating Therapeutic Potential in Modulating Brain Circuits Commonly Dysregulated in Neurobehavioral Disorders
Feb 7, 2017
BlackThorn Therapeutics Names Biotech Industry Veteran Gregory Vontz as Chief Executive Officer
Jan 5, 2017
BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing
Oct 20, 2016
Endpoints News: Backed by Neuro Enthusiast ARCH, Upstart BlackThorn Tackles Some Tough Targets with $40M Round
Oct 20, 2016
Forbes: Arch, J&J Join $40M Bet on New Approach to Neurobehavioral Drug Discovery
1 2
Get In Touch

Contact Us

Address
Email
JLABS

329 Oyster Point Blvd
3rd Floor
South San Francisco, CA 94080

Cambridge Innovation Center

1 Broadway
14th Floor
Cambridge, MA 02142

Stay Connected

Get BlackThorn News & Updates